IOCB Prague

IOCB Prague, established in 1953, is a distinguished research institute operating under the Czech Academy of Sciences. It focuses on organic chemistry, biochemistry, and related fields, with a strong emphasis on applications in medicine and environmental science. The institute is internationally recognized for its significant contributions, particularly in developing critical drugs for HIV and HBV. Its scientific endeavors are supported by a substantial team, evidenced by hashtags indicating #50_plus_scientists and #10_plus_engineering_and_tech.

With a single primary location, IOCB Prague manages operations involving 500 - 1,000 employees, reflecting a significant scale for a specialized research entity. Its revenue stands at $39.1M, underscoring its financial capacity to support advanced research and development. The institute's work encompasses coordinating complex scientific projects and producing reference standards and specialized substances, including protein sequencing services. This operational scope aligns with its B2B and European focus, as suggested by hashtags like #b2b and #eu.

IOCB Prague plays a vital role in advancing scientific knowledge and its practical application. Beyond its drug development achievements, the institute actively participates in academic education, supervising master's and doctoral theses, thereby nurturing the next generation of scientists. Its commitment to excellence is reflected in its product descriptors such as "internationally recognized," "scientific reference standard," and "special protein sequencing." For insights into the personnel driving these innovations, one can Meet IOCB Prague's team.